A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Part of paid clinical trials in Irvine, California.
- Sponsor
- Spyre Therapeutics, Inc.
- Study ID
- NCT07766005
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Hidradenitis Suppurativa (HS)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- SPY072 — DRUGSolution for SC injection
- Placebo — DRUGMatching placebo for SC injection
- bimekizumab — DRUGAdvanced standard of care
Study Details
This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.
Key Dates
- First listed
- Aug 14, 2026
- Start date
- Sep 30, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 31, 2027
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SPY072 + bimekizumabParticipants receive SPY072 + bimekizumab
- Placebo Comparator: Placebo + bimekizumabParticipants receive matching placebo for SPY072 + bimekizumab
Primary Outcome Measure
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) [ Time Frame: Week 16 ]
Central Contacts
- SKYLIGHT Trial Center1-702-602-7976
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site 111 | Irvine | California | 92614 | SKYLIGHT Trial Center |
| Site 101 | Indianapolis | Indiana | 46250 | SKYLIGHT Trial Center |
| Site 100 | Bowling Green | Kentucky | 42104 | SKYLIGHT Trial Center |
| Site 108 | Baton Rouge | Louisiana | 70809 | SKYLIGHT Trial Center |
| Site 110 | New Orleans | Louisiana | 70115 | SKYLIGHT Trial Center |
| Site 103 | Boston | Massachusetts | 02115 | SKYLIGHT Trial Center |
| Site 102 | New York | New York | 10023 | SKYLIGHT Trial Center |
| Site 104 | The Bronx | New York | 10455 | SKYLIGHT Trial Center |
| Site 109 | Mt. Pleasant | South Carolina | 29464 | SKYLIGHT Trial Center |
| Site 105 | Dallas | Texas | 75246 | SKYLIGHT Trial Center |
| Site 107 | Tyler | Texas | 75703 | SKYLIGHT Trial Center |
| Site 106 | Mill Creek | Washington | 98012 | SKYLIGHT Trial Center |
Related Studies
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPHASE3 · Recruiting · Incyte Corporation · Birmingham, Alabama
- A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) TherapeuticRecruiting · Sonoma Biotherapeutics, Inc. · San Francisco, California
- 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)PHASE1 · Recruiting · Wynn Medical Center · Rosemead, California
- Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaPHASE2 · Recruiting · Incyte Corporation · Birmingham, Alabama